Role of Cefiderocol in Multidrug-Resistant Gram-Negative Central Nervous System Infections: Real Life Experience and State-of-the-Art

被引：6

作者：

Sollima, Alessio ^{[1
,2
]}

Rossini, Francesco ^{[1
,2
]}

Lanza, Paola ^{[3
]}

Pallotto, Carlo ^{[4
]}

Meschiari, Marianna ^{[5
]}

Gentile, Ivan ^{[6
]}

Stellini, Roberto ^{[1
,2
]}

Lenzi, Angelica ^{[1
,2
]}

Mule, Alice ^{[1
,2
]}

Castagna, Francesca ^{[1
,2
]}

Lorenzotti, Silvia ^{[3
]}

Amadasi, Silvia ^{[2
,3
]}

Van Hauwermeiren, Evelyn ^{[3
]}

Saccani, Barbara ^{[3
]}

Fumarola, Benedetta ^{[3
]}

Signorini, Liana ^{[3
]}

Castelli, Francesco ^{[1
,3
]}

Matteelli, Alberto ^{[1
,2
,3
]}

机构：

[1] Univ Brescia, Dept Clin & Expt Sci, Unit Infect & Trop Dis, I-25123 Brescia, Italy

[2] ASST Spedali Civili Brescia, I-25123 Brescia, Italy

[3] ASST Spedali Civili Brescia, Unit Infect & Trop Dis, I-25123 Brescia, Italy

[4] Univ Perugia, Santa Maria Misericordia Hosp, Dept Med & Surg, Infect Dis Clin, I-06132 Perugia, Italy

[5] Univ Modena & Reggio Emilia, Infect Dis Unit, Azienda Osped Univ Modena, I-41124 Modena, Italy

[6] Univ Naples Federico II, Dept Clin Med & Surg, I-80131 Naples, Italy

来源：

ANTIBIOTICS-BASEL | 2024年 / 13卷 / 05期

关键词：

cefiderocol; central nervous system; gram-negative; therapeutic drug monitoring; CNS infections; neurosurgical device infections;

D O I：

10.3390/antibiotics13050453

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

Cefiderocol is a new molecule effective against multidrug-resistant (MDR) Gram-negative pathogens. Currently, there is limited evidence regarding the use of cefiderocol in central nervous system (CNS) infections. Data on the cerebrospinal fluid penetration rate of cefiderocol are limited and heterogeneous, and there is no consensus on the dosing scheme of cefiderocol to penetrate the blood-brain barrier. We present a case series and a literature review of CNS infections caused by MDR pathogens that were treated with cefiderocol: some of these patients were treated with different dose schemes of cefiderocol and underwent therapeutic drug monitoring both on plasma and cerebrospinal fluid (CSF). The CSF penetration rates and the clinical outcomes were evaluated.

引用

页数：9

共 21 条

[1]

Abdul-Aziz MH, 2020, INTENS CARE MED, V46, P1127, DOI [10.47832/2757-5403.2-2.1, 10.1007/s00134-020-06050-1]

[2] Pharmacokinetics, Pharmacodynamics, and Dosing Considerations of Novel β-Lactams and β-Lactam/β-Lactamase Inhibitors in Critically Ill Adult Patients: Focus on Obesity, Augmented Renal Clearance, Renal Replacement Therapies, and Extracorporeal Membrane Oxygenation [J].

Bakdach, Dana ;

Elajez, Reem ;

Bakdach, Abdul Rahman ;

Awaisu, Ahmed ;

De Pascale, Gennaro ;

Hssain, Ali Ait .

JOURNAL OF CLINICAL MEDICINE, 2022, 11 (23)

[3] Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial [J].

Bassetti, Matteo ;

Echols, Roger ;

Matsunaga, Yuko ;

Ariyasu, Mari ;

Doi, Yohei ;

Ferrer, Ricard ;

Lodise, Thomas P. ;

Naas, Thierry ;

Niki, Yoshihito ;

Paterson, David L. ;

Portsmouth, Simon ;

Torre-Cisneros, Julian ;

Toyoizumi, Kiichiro ;

Wunderink, Richard G. ;

Nagata, Tsutae D. .

LANCET INFECTIOUS DISEASES, 2021, 21 (02) :226-240

[4]

Colombo Francesco, 2022, Infez Med, V30, P454, DOI [10.53854/liim-3003-15, 10.53854/liim-3003-15]

[5] Implications of Augmented Renal Clearance on Drug Dosing in Critically Ill Patients: A Focus on Antibiotics [J].

Hobbs, Athena L. V. ;

Shea, Katherine M. ;

Roberts, Kirsten M. ;

Daley, Mitchell J. .

PHARMACOTHERAPY, 2015, 35 (11) :1063-1075

[6] Population Pharmacokinetic and Pharmacokinetic/ Pharmacodynamic Analyses of Cefiderocol, a Parenteral Siderophore Cephalosporin, in Patients with Pneumonia, Bloodstream Infection/Sepsis, or Complicated Urinary Tract Infection [J].

Kawaguchi, Nao ;

Katsube, Takayuki ;

Echols, Roger ;

Wajima, Toshihiro .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2021, 65 (03)

[7] Plasma and cerebrospinal fluid concentrations of cefiderocol during successful treatment of carbapenem-resistant Acinetobacter baumannii meningitis [J].

Kufel, Wesley D. ;

Abouelhassan, Yasmeen ;

Steele, Jeffrey M. ;

Gutierrez, Ramiro L. ;

Perwez, Talha ;

Bourdages, George ;

Nicolau, David P. .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2022, 77 (10) :2737-2741

[8] Cerebrospinal fluid concentrations of cefiderocol during the treatment of extensively drug-resistant Pseudomonas aeruginosa ventriculitis [J].

Luque-Paz, David ;

Bennis, Youssef ;

Jaubert, Paul ;

Dubee, Vincent ;

Wolff, Michel ;

Mortaza, Satar .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2022, 77 (06) :1787-1789

[9] Clinical Cure of a Difficult-to-Treat Resistant Pseudomonas aeruginosa Ventriculitis Using Cefiderocol: A Case Report and Literature Review [J].

Marcelo, Cristina ;

de Gea Grela, Alejandro ;

Martinez Palazuelos, Maria ;

Veganzones, Javier ;

Grandioso, David ;

Diaz-Pollan, Beatriz .

OPEN FORUM INFECTIOUS DISEASES, 2022, 9 (08)

[10] Analytical validation of a novel UHPLC-MS/MS method for 19 antibiotics quantification in plasma: Implementation in a LC-MS/MS Kit [J].

Mula, Jacopo ;

Chiara, Francesco ;

Manca, Alessandra ;

Palermiti, Alice ;

Maiese, Domenico ;

Cusato, Jessica ;

Simiele, Marco ;

De Rosa, Francesco Giuseppe ;

Di Perri, Giovanni ;

De Nicolo, Amedeo ;

D'Avolio, Antonio .

BIOMEDICINE & PHARMACOTHERAPY, 2023, 163

← 1 2 3 →